An orthogonal transcription system enables high-efficiency rescue of measles virus-based vaccine vectors against multiple pathogens.
The new orthogonal transcription system significantly enhances the efficiency of rMeV vector rescue, showing promise for rapid vaccine development, though human studies are needed.
Where it sits
this study against the rest of the cjc-1295 without dac (modified grf 1-29) corpusSummary and findings
The study developed a high-efficiency rescue platform for recombinant measles virus (rMeV) vectors using an orthogonal transcription system. This system enhanced rescue efficiency by more than 50-fold compared to traditional methods. Immunization in golden Syrian hamsters showed high antibody titers with no adverse effects.
Abstract
Recombinant measles virus (rMeV) vectors are promising platforms for vaccine development against emerging infectious diseases due to their safety, stability, and potent immunogenicity. However, conventional rMeV rescue systems frequently exhibit low efficiency, thereby constraining their scalability and throughput. In this study, we developed a modular, helper-virus-free and high-efficiency rescue platform based on an orthogonal transcription system utilizing orthogonal promoters and engineered RNA polymerases fused to an mRNA capping enzyme. This innovative system facilitated robust cytoplasmic manufacture of both genomic and auxiliary components, eliminating the need for helper virus co-infection (such as modified vaccinia virus) and enhancing rescue efficiency by more than 50-fold relative to traditional rescue approaches. Utilizing this technology, we demonstrated the versatility of the platform by successfully generating six rMeV-based vaccine antigen candidates from influenza virus, <i>Pseudomonas aeruginosa</i>, and <i>Brucella</i> spp. All rescued vaccine candidates exhibited stable transgene expression, sustained replication, and strong antigen production. Immunization studies in golden Syrian hamsters verified that the vaccine candidates elicited high titers of neutralizing and antigen-specific antibodies without any observable adverse effects. These results demonstrate that our orthogonal transcription-based platform facilitates the efficient and safe production of rMeV vectors and provides a proof-of-concept methodological framework for the rapid development of vaccine candidates.
Background
Recombinant measles virus vectors are considered promising for vaccine development due to their safety and immunogenicity. However, traditional rescue systems for these vectors often have low efficiency, limiting their scalability. This study addresses the need for a more efficient rescue system to enhance the development of rMeV-based vaccines.
Methods
The study utilized an orthogonal transcription system with orthogonal promoters and engineered RNA polymerases fused to an mRNA capping enzyme. This system was designed to facilitate cytoplasmic manufacture of genomic and auxiliary components without the need for helper virus co-infection. The platform was tested by generating six rMeV-based vaccine candidates targeting influenza virus, Pseudomonas aeruginosa, and Brucella spp. Immunization studies were conducted in golden Syrian hamsters.
Results
The orthogonal transcription system increased rescue efficiency by more than 50-fold compared to traditional methods. All six vaccine candidates showed stable transgene expression, sustained replication, and strong antigen production. Immunization in golden Syrian hamsters resulted in high titers of neutralizing and antigen-specific antibodies, with no observable adverse effects.
Interpretation
The study demonstrates a significant improvement in the efficiency of rMeV vector rescue, which could accelerate vaccine development. While the results in hamsters are promising, the clinical significance for humans remains uncertain until further studies are conducted. The lack of human data and reliance on animal models are notable limitations.
Key findings
- Rescue efficiency enhanced by more than 50-fold.
- Six rMeV-based vaccine candidates generated.
- Stable transgene expression and strong antigen production observed.
- High titers of neutralizing and antigen-specific antibodies in hamsters.
- No observable adverse effects in immunization studies.
Limitations
- Animal model only, no human data.
- Study conducted in golden Syrian hamsters.
- Potential differences in human immune response not addressed.